je.st
news
Tag: therapy
Cancer therapy deal with Bristol-Myers Squibb boosts Five Prime drug
2014-11-25 08:34:39| Biotech - Topix.net
Five Prime Therapeutics Inc. snagged a deal with Bristol-Myers Squibb Co. around one of the leading drugs in the emerging class of cancer-fighting drugs known as immune checkpoint inhibitors.
Endo to pay $25M for nasal testosterone replacement therapy
2014-11-25 00:20:24| Biotech - Topix.net
Endo International made a bigger push into the testosterone replacement therapy market Monday by agreeing to acquire the rights to Natesto for $25 million. Natesto is the only testosterone nasal gel approved by the Food and Drug Administration as a replacement therapy for adult males with hypogonadism - a condition where sex glands produce little or no sex hormones.
Tags: pay
therapy
replacement
25m
J&J Hepatitis C Drug Wins U.S. Approval as Therapy With Sovaldi
2014-11-06 15:21:29| Food - Topix.net
Johnson & Johnson won U.S. approval for its hepatitis C drug Olysio to be used in combination with Gilead Sciences Inc.'s Sovaldi, making it the second all-oral treatment available for the most common form of the virus. The Food and Drug Administration cleared the once-daily treatment for patients with hepatitis C genotype 1, J&J said yesterday in a statement.
Tags: with
drug
approval
therapy
New Studies Investigating the Use of KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time
2014-11-06 15:08:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. By Year End, Data on KEYTRUDA in Seven Tumor Types Will Have Been Presented WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA (pembrolizumab) the companys anti-PD-1 therapy in advanced melanoma in comparison to chemotherapy, and in relapsed/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients
2014-11-03 11:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Phase 3 Clinical Trial Enrollment Scheduled to Start by the End of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once-daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection. Results were presented as a poster (#0434) and oral presentation by Dr. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCarmen de Gourville, 267-664-0146orInvestors:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
study
phase
patients
Sites : [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] next »